✨ Medicines Distribution Consents
832 NEW ZEALAND GAZETTE, No. 29 8 MARCH 2012
Product: Bicalutamide
Active Ingredient: Bicalutamide 50mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Dr Reddy’s New Zealand Limited
Manufacturer: Dr Reddy’s Laboratories Limited, Andhra Pradesh, India
Product: Elonva
Active Ingredient: Corifollitropin alfa 0.2mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Vetter Pharma-Fertigung GmbH & Co Kg, Ravensburg, Germany
Product: Elonva
Active Ingredient: Corifollitropin alfa 0.3mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Vetter Pharma-Fertigung GmbH & Co Kg, Ravensburg, Germany
Product: Menactra
Active Ingredient: Meningococcal polysaccharide 4μg of each of Groups A, C, Y & W-135, each separately conjugated to diphtheria toxoid, 48μg total
Dosage Form: Solution for injection
New Zealand Sponsor: Sanofi-Aventis New Zealand Limited
Manufacturer: Sanofi Pasteur Inc, Pennsylvania, United States of America
Product: Viramune
Active Ingredient: Nevirapine 200mg
Dosage Form: Tablet
New Zealand Sponsor: Boehringer Ingelheim (NZ) Limited
Manufacturer: Boehringer Ingelheim Roxane Inc, Ohio, United States of America
Product: Viramune
Active Ingredient: Nevirapine hemihydrate 10.35mg/mL equivalent to Nevirapine 10mg/mL
Dosage Form: Oral suspension
New Zealand Sponsor: Boehringer Ingelheim (NZ) Limited
Manufacturer: Boehringer Ingelheim Roxane Inc, Ohio, United States of America
Dated this 1st day of March 2012.
Dr DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go1321
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Micardis
Active Ingredient: Telmisartan 40mg
Dosage Form: Tablet
New Zealand Sponsor: Boehringer Ingelheim (NZ) Limited
Manufacturer: Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany
Product: Micardis
Active Ingredient: Telmisartan 80mg
Dosage Form: Tablet
New Zealand Sponsor: Boehringer Ingelheim (NZ) Limited
Manufacturer: Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany
Dated this 1st day of March 2012.
Dr DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go1322
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Next Page →
✨ LLM interpretation of page content
🏥
Consent to the Distribution of New Medicines
(continued from previous page)
🏥 Health & Social Welfare1 March 2012
Medicines Act, New Medicines, Distribution, Bicalutamide, Elonva, Menactra, Viramune
- Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social Welfare1 March 2012
Medicines Act, New Medicines, Distribution, Micardis, Telmisartan
- Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health
🏥 Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social WelfareMedicines Act, Provisional Consent, New Medicine
NZ Gazette 2012, No 29